Podcasts about Malignancy

Listen to JCO Global Oncology's Art of Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India” by Dr. Vangipuram Harshil Sai, who is a fourth semester medical student at All India Institute of Medical Sciences. The article is followed by an interview with Harshil Sai and host Dr. Mikkael Sekeres. Sai shares his personal reflection of a visit which transformed into an education in silence, stigma, and the unseen aftermath of survivorship for young women in India. TRANSCRIPT Narrator: Whispers After the Cure: Reflections on Marriage and Malignancy in India, Vangipuram, Harshil Sai   A Summer Afternoon and A Story That Stayed The summer break of my fourth semester of medical school offered a fleeting reprieve from the relentless immersion in textbooks and caffeine-fueled study sessions. I had envisioned a few weeks of rest—a pause from the algorithms of diagnosis and the grind of multiple-choice questions that had become my daily rhythm. But one humid afternoon altered that plan. I accompanied my mother—a senior medical oncologist—to her clinic in a Tier 2 city in Southern India. Over the years, I had seen her not just as a clinician but as a quiet force of empathy. She was one of those remarkable physicians who listened not just to symptoms but also to stories. Her practice was rooted in presence, and her calm resilience often made my academic anxieties seem trivial. I settled into a corner chair in the waiting area, where the air was tinged with antiseptic and that uncomfortable waiting room stillness—an alert hush between uncertainty and news. Patients waited in quiet constellations: a man turning the same page of a newspaper, a teenage girl watching her intravenous drip as if it held answers, and a couple clasping hands without meeting eyes. It was in this atmosphere of suspended quiet that Aarthi entered. She was a young woman whose presence was composed yet tentative. Her story would become a quiet inflection point in my understanding of medicine. She was 24 years old, embodying the aspirations tied to a recent engagement. A postgraduate in English literature and a practicing psychologist; she carried herself with a rare blend of intellect, poise, and cultural grace that, in the eyes of many families, made her a deeply desirable bride. Her sari was immaculately draped, her posture measured and calm, yet in the way her fingers intertwined and her eyes briefly lowered, there was a trace of vulnerability—a shadow of the turmoil she carried within. She came alone that day, stepping into the waiting room with a composed demeanor that only hinted at the weight she bore in silence. What began as a day to observe became the beginning of something far more enduring: a glimpse into how healing extends beyond treatment—and how survival, though silent, often speaks the loudest. The Diagnosis That Changed the Wedding The consultation was precipitated by a clinical presentation of persistent neck fullness, low-grade fevers, and drenching night sweats, which had prompted a fine-needle aspiration before her visit. The atmosphere in the room held an implicit gravity, suggesting a moment of significant change. My mother, with her characteristic composure, initiated a diagnostic process with a positron emission tomography-computed tomography and biopsy. As usual, her steady presence provided reassurance amid the uncertainty. A week later, the diagnosis of classic Hodgkin lymphoma, stage IIB, was confirmed. Rapid initiation of ABVD chemotherapy would provide an almost certain pathway to remission and an excellent prognosis. Yet, this clinical assurance did not extend to personal tranquility. Aarthi made a deliberate choice to share the diagnosis with her fiancé—a considerate and empathetic individual from a well-regarded family. Their wedding preparations were already underway with gold reserves secured and a vibrant WhatsApp group of 83 members chronicling the countdown to their big day. Shortly thereafter, a prolonged silence settled, eventually broken by a call from a family member—not the fiancé—indicating that the family had decided to terminate the engagement because of apprehensions about future stability. The union dissolved without public discord, leaving Aarthi to navigate the subsequent journey independently. As expected, 6 months of chemotherapy culminated in a clean scan. Her physical health was restored, but an emotional chasm remained, unrecorded by clinical metrics. Yet beneath that silence was a quiet resilience—a strength that carried her through each cycle of treatment with a resolve as steady as any celebrated elsewhere. The regrowth of her hair prompted a conscious decision to trim it shorter, seemingly an assertion of autonomy. Her discourse on the illness shifted to the third person, suggesting a psychological distancing. Her reactions to inquiries about the terminated engagement were guarded. She would yield only a restrained smile, which intimated a multifaceted emotional response. Her remission was certain, yet the world she stepped back into was layered with quiet hurdles—social, cultural, and unseen—barriers far more intricate than the disease itself. Survivorship Without A Map In the weeks that followed Aarthi's diagnosis, I began to notice a quiet but consistent pattern in the oncology clinic—one that extended beyond medical recovery into the unspoken social aftermath. Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable. Proposals that had once moved forward with confidence were paused or reconsidered after disclosure. In some cases, financial discussions came with requests for additional support framed as reassurance rather than rejection. These changes were seldom explicit. Yet, across time, they pointed to a deeper uncertainty—about how survivorship fits into the expectations of traditional life scripts. For women like Aarthi, the narrative shifted toward caution. There were subtle inquiries about reproductive potential or disease recurrence and private deliberations over disclosure during matrimonial discussions, even within educated circles. Meanwhile, my observation of the disparity in how survivorship was interpreted across genders in our country left a profound mark on me. A 31-year-old male investment banker who had recovered from testicular cancer was hailed in local media as a testament to fortitude. Male patients seemed to gain social capital from their cancer journeys. This suggested a cultural framework where female value was quietly reassessed, influencing their post-treatment identity through unstated societal perceptions. Digital Ghosting and the New Untouchability Within the digital landscape of curated profiles and algorithmic matchmaking, the reassessment of female survivorship acquired a new dimension. In one instance, a sustained exchange of text messages ended abruptly following the mention of cancer remission. The final message remained unanswered. This form of silent disengagement—subtle, unspoken, and devoid of confrontation—highlighted how virtual spaces can compound post-treatment vulnerability. Designed to foster connection, these platforms sometimes amplified social distance, introducing a modern form of invisibility. Similar to employment status or religion, a cancer history has become another addition to a checklist used to evaluate compatibility. When Medicine Ends, but Society Does Not Begin As a medical student, I felt a growing discomfort. Our curriculum equips us to manage treatment protocols and survival metrics but rarely prepares us for the intangible burdens that persist after cure. What captures the weight of a canceled engagement? What framework supports the quiet reconstruction of identity after remission? Aarthi's path, echoed by many others, revealed a dissonance that medicine alone could not resolve. The challenge was not solely the illness but the reality that she was now unqualified to return to her normal life. Medicine delivers clean scans and structured follow-up, but social reintegration is less defined. In that space between biological recovery and social acceptance, cancer survivors often stand at the edge of wholeness—clinically well but navigating a quieter uncertainty. A Different Ending Two years later, Aarthi's journey took a quiet turn. At a spiritual retreat in Bengaluru, she met an ear, nose, and throat resident who had lost his father to lung cancer. Their connection, shaped by shared experiences, evolved into a partnership grounded in empathy and mutual respect. They married the following year. Their invitation carried a brief but powerful line: “Cancer Survivor. Love Thriver. Come celebrate both.” Today, they comanage a private hospital in Hyderabad. Aarthi leads psycho-oncology services, whereas her partner performs surgeries. He often notes that her presence brings a calm to the clinic that no medication can replicate. Aarthi's journey continues to guide me as I progress through my medical training, reminding me that cure and closure often follow separate paths. Healing, I have come to understand, extends beyond the clinic. It often unfolds in quieter spaces where scans no longer guide us. The real curriculum in oncology lies not only in staging and response rates but in recognizing the many transitions—social, emotional, and cultural—that survivors must navigate long after treatment has concluded. Social stigma is often a second metastasis—undetectable by imaging but present in tone, hesitation, and traditions that quietly redefine survivorship. For many women of marriageable age, treatment marks not the end of struggle but the start of another kind of uncertainty. These survivors carry wounds that do not bleed. Yet, they persist, navigate, and redefine strength on their own terms. Aarthi's quiet resilience became a point of reckoning for me, not as a medical case, but as a guide. Her story is not one of illness alone, but of dignity quietly reclaimed. “Out of suffering have emerged the strongest souls; the most massive characters are seared with scars.”—Khalil Gibran.   Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm professor of medicine and chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. In oncology, we often focus on treatment and a way to find a cure. But what about the expectations and challenges a patient may face from their diagnosis, and even discrimination, especially in different cultures? Today, we're going to examine that space with Harshil Vangipuram, a medical student from India whose JCO Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India," touches on this complexity after treatment. Harshil, thank you for contributing to JCO Global Oncology and for joining us to discuss your article. Harshil Vangipuram: Thank you for having me, Dr. Sekeres. I was raised by a family of oncologists, my mother being a senior medical oncologist and father a senior radiation oncologist. I had exposure to contrasting worlds, which were resource constrained and a cutting edge technology world. And I have unfulfilled curiosity, and I'm still learning, forming ideals. I also see patients as my teachers, so I think that might be helpful. Mikkael Sekeres: Thank you so much for a little bit of that background. So, tell us a little bit about your journey through life so far. Where were you born and where did you do your education? Harshil Vangipuram: I was born in a state called Gujarat in the western part of India. My father got transferred to the southern part of India, so I did my education there. That's it, yeah. Mikkael Sekeres: Okay. That's enough. You're not that old. You haven't had the sort of training and final job that a lot of us have gone through. So, what about your story as a writer? How did you first get interested in writing, and how long have you been writing reflective or narrative pieces? Harshil Vangipuram: I read some books from Indian authors and from foreign, too. And they actually inspired me how patient care was being seen around globally. I always used to carry a hand note. I used to write what I used to see in the clinical postings here at AIIMS. And actually, journaling started as a stress relief for me, and slowly, after hearing patients' stories, it almost became an obligation to write about them. Mikkael Sekeres: Obligation, you use that word, which is such an interesting one. How did writing become an obligation? What did you feel obliged to do when writing about some of the patients you were seeing for the first time? Harshil Vangipuram: Many of them were having struggles which were not seen by everybody. And I got astonished by their confidence and resilience in those situations. So, I thought that I should write about them so that everybody knows about it. And these social stigmas were never talked by anyone around them. So, I felt that if I could voice them, others might eventually know about them. So, that's pretty much the reason I wrote. Mikkael Sekeres: It's so interesting. The people we meet every single day, particularly in hematology oncology, bring such fascinating backgrounds to us, and they're backgrounds that may be unfamiliar to us. And I think that as doctors and writers, we do often feel obliged to tell their stories from the mountaintops, to let other people in on some of the aspects of life and medical care that they're going through and just how inspiring some of these patients can be. Harshil Vangipuram: Yeah, yeah, very true. Very true. Mikkael Sekeres: You mentioned that your mom is a medical oncologist. What kind of influence did she have on your decision to enter medicine and perhaps your own specialty one day? Harshil Vangipuram: Observing my mother practice influenced a lot, and she taught me that medicine is not only about treating a patient, but also listening to their problems. It may be more present in the room. The textbooks I read didn't capture live experiences. I always thought that stories will stay with people longer than actual survival curves. Writing filled that gap between what I studied and what I felt in the OPD. Mikkael Sekeres: It's a great phrase you just whipped out. Patients' stories will stay with us longer than survival curves. Can you tell us a little bit about where her clinic is located? You said in southern India. Can you describe the types of patients she sees? Harshil Vangipuram: It's a small town called Nellore in Andhra Pradesh state. The patients are, most of the time, from a rural population where decisions are mostly family-driven and there's a tight community surveillance and the stigmas are more overt, too. A few of them can be from urban population also, but they have subtler discriminations towards stigmas. Mikkael Sekeres: Can you explain a little further what you mean by decisions are often family-driven? Harshil Vangipuram: If we take marriage, it is often seen as an alliance between two families that are trying to increase their social value, their economic status, and respect in the society. In arranged marriages, for suppose, it's basically driven between these concepts. Mikkael Sekeres: I don't know if it's too personal to ask, but are your parents in an arranged marriage? Harshil Vangipuram: No, not at all. Mikkael Sekeres: So not all the marriages in the clinic are arranged marriages. Harshil Vangipuram: Yeah. Mikkael Sekeres: You know, when you said that decisions are family-driven, you mentioned that people are in arranged marriages. And I wanted to talk a little bit about the stigma you highlight in your essay. I'll talk about that in a second. I thought you were going to go down a route about medical decisions being family-driven, meaning people have to support their families, and getting medical care is costly and takes time away from work, and that sometimes influences decisions about treating cancer. What examples have you seen of that in shadowing your mom? Harshil Vangipuram: I have seen patients who have Hodgkin's lymphoma, breast cancer, and ovarian cancer, who were in the age of 25 to 35, who were getting married. Many of them actually got their engagements broken. And many of them got rejected at matrimonial apps. Many of them also had been told to increase the dowry that is given actually in the form of financial security. Mikkael Sekeres: In your essay, you describe a woman who is engaged and who has a new diagnosis of Hodgkin lymphoma. Can you talk a little bit about the process of getting engaged and marrying in southern India? Harshil Vangipuram: We have the arranged marriage, love marriage, and hybrid, which is kind of arranged and kind of in love. Mostly, these problems really occur in arranged marriages. In love marriages, we don't see that that often because both are understanding about themselves and their families. And both families actually accept them both. Mikkael Sekeres: What's the process of going through an arranged marriage? What happens? Harshil Vangipuram: It can be through parents, relatives, or any known ones or through peers. We just find a man or woman who has a similar caste, who has a good financial income, and people who are respected by the society. And obviously, both the families should have aligned interests for them to accept the marriage. Mikkael Sekeres: About how often are marriages arranged and how often are they love marriages in southern India where you live? Harshil Vangipuram: Almost 90% of the marriages are arranged here. Mikkael Sekeres: Wow. So, your parents were unusual then for having a love marriage. Harshil Vangipuram: Yeah. Mikkael Sekeres: In your essay, you write, and I'm going to quote you now, "Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable." Wow, that's a really moving statement. I'm curious, what stories have you seen where, in your words, women became less suitable as a marriage prospect? Harshil Vangipuram: For women, the most important thing in a marriage is, what do you call, a family honor, fertility, and economic status in the community. So, after a long dose of chemo, many people think that people become infertile. In India, basically, we have many misconceptions and stigmas. So, people obviously think that people who have got cancer can spread it to their children or are infertile and are often excluded out of the society as a marriage prospect. Mikkael Sekeres: Gosh, that must be devastating. Harshil Vangipuram: Yeah. Mikkael Sekeres: Does the same occur for men? So, is it also true that if a man has cancer, that he is perceived as less fertile, or it may be perceived that he can pass the cancer on to children? Harshil Vangipuram: Here, after a man beats cancer, they start to celebrate it, like they have achieved something, and it's not like that for a woman. Mikkael Sekeres: In your essay, you do write about a happy ending for one woman. Can you tell us about that? Harshil Vangipuram: Yeah, a cancer survivor obviously met her true love of life in Bengaluru, who was an ENT resident then. And his father died from lung cancer. So obviously, he knew what it felt to beat cancer. Mikkael Sekeres: Yeah, he'd been through it himself. And the irony, of course, is that most cancer treatments that we give do not lead to infertility, so it's a complete misperception. Harshil Vangipuram: Yeah. Mikkael Sekeres: Tell us about your future. What are the next steps for you in your training and what do you hope to specialize in and practice? Harshil Vangipuram: Actually, I'm working on another paper which involves financial toxicity after treatment and post treatment depression. I think it would be completed in another year. And after that, after my med school is completed, I think I'm going to pursue oncology or hematology as my branch of interest. Mikkael Sekeres: Wonderful. It's thrilling to hear that somebody who is as sensitive to his patients and both their medical needs and their needs outside of medicine will be entering our field. It'll be great to know that you'll be taking care of our future patients. Harshil Vangipuram: The pleasure is all mine, sir. Mikkael Sekeres: Harshil Vangipuram, I want to thank you for choosing JCO Cancer Stories: The Art of Oncology and for submitting your great piece, "Whispers After the Cure: Reflections on Marriage and Malignancy in India" to JCO Global Oncology. To our listeners, if you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres from the Sylvester Cancer Center, University of Miami. Have a good day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes:Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio:Dr Vangipuram Harshil Sai is a fourth semester medical student at All India Institute of Medical Sciences. Additional Reading Impact of Gender of the Child on Health Care–Seeking Behavior of Caregivers of Childhood Patients With Cancer: A Mixed-Methods Study | JCO Global Oncology

In this episode of SurgOnc Today, SSO Peritoneal Surface Malignancy Disease Site Working Group members Dr. Alissa Greenbaum and Dr. Omar Llaguna moderate a discussion with Dr. Maheswari Senthil of UC Irvine and Dr. Richard Alexander of the Rutgers Cancer Institute of New Jersey to dive deep into the history of the development of regional therapies such as HIPEC and PIPAC in the United States. The expert discussants answer tough questions regarding the ethical considerations of modern clinical trials and the implementation of experimental therapies into practice.

In this episode, host Jonathan Sackier is joined by Andrew Dunbar, Assistant Professor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center, Houston, USA. Dunbar discusses his research into myeloproliferative neoplasms, what drives disease progression and resistance, and promising targets for treatment, while reflecting on the mission of his lab and what lies ahead for the field.  Timestamps  00:00 – Introduction  02:29 – One thing people should know about myeloproliferative neoplasms  05:01 – Dunbar's background and research focus  08:00 – What would Dunbar do if not science and medicine?  10:24 – The basics of myeloproliferative neoplasms  14:30 – Myeloproliferative neoplasm diagnosis and treatment  16:49 – What drives disease progression and resistance?  18:30 – The mission of Dunbar's lab  21:23 – Development of AJ1-11095  22:54 – Balancing the complexity of disease modelling with urgent clinical needs  24:03 – Promising targets and pathways  26:35 – What's on the horizon?  28:40 – Three wishes 

In this episode of the Clinical Update podcast, MIMS Learning editor Pat Anderson and medical editor Dawn Liz Powell discuss common and less common presentations of nasal problems.This podcast draws on the expertise of MIMS Learning's professional clinical writers and speakers, to bring you key learning points on nasal problems.  Potential problems include loss of sense of smell, obstruction, discharge and pain, with a large variety of potential causes. Some patients, including older people and those of Chinese heritage, may be more at risk of malignancy.Educational objectivesAfter listening to this podcast, healthcare professionals should be better able to: Recall red flag symptoms associated with nose problemsList causes of loss of sense of smellRecall management of nosebleeds and their possible causesReflect on hayfever management and the role of immunotherapyConsider increased risk of malignancy in key patient groupsYou can access the website version of this podcast, along with a list of key learning points, on MIMS Learning - and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.MIMS LearningSubscribe to MIMS LearningNasal problems - red flag symptomsGuidance update: latest NICE guidelines on neurological conditionsENT emergenciesEpistaxis - red flag symptomsHayfever: clinical reviewFacial pain - red flag symptoms Hosted on Acast. See acast.com/privacy for more information.

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/british-studies

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/european-studies

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist. Learn more about your ad choices. Visit megaphone.fm/adchoices

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Agnes Arnold-Forster's book The Cancer Problem: Malignancy in Nineteenth-Century Britain (Oxford UP, 2021) offers the first medical, cultural, and social history of cancer in nineteenth-century Britain. It begins by looking at a community of doctors and patients who lived and worked in the streets surrounding the Middlesex Hospital in London. It follows in their footsteps as they walked the labyrinthine lanes and passages that branched off Tottenham Court Road; then, through seven chapters, its focus expands to successively include the rivers, lakes, and forests of England, the mountains, poverty, and hunger of the four nations of the British Isles, the reluctant and resistant inhabitants of the British Empire, and the networks of scientists and doctors spread across Europe and North America. The Cancer Problem argues that it was in the nineteenth century that cancer acquired the unique emotional, symbolic, and politicized status it maintains today. Through an interrogation of the construction, deployment, and emotional consequences of the disease's incurability, this book reframes our conceptualization of the relationship between medicine and modern life and reshapes our understanding of chronic and incurable maladies, both past and present. Rachel Pagones is chair of the doctoral program in acupuncture and Chinese medicine at Pacific College of Health and Science in San Diego and a licensed acupuncturist.

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

The rate of cancer and cancer malignancy differ greatly among mammalian species. The placental – maternal interface is also highly variable between placental mammals. This lecture will discuss recent advances that suggest that there is a causal connection between the evolution of placental biology and the biology and rate of cancer malignancy. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40694]

Drs Sara Horst and Jordan Axelrad Discuss Risks of Malignancy, Infection With IBD Therapies by Gastroenterology Learning Network

Send us a text

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Editor-in-Chief Cecelia E. Schmalbach, MD, MSc, is joined by senior author David Goldenberg, MD, to discuss role of estrogen in developing thyroid malignancy as outlined in the paper “Elevated Risk of Thyroid Malignancy in Biological Males Taking Estrogen Hormone Therapy” which published in the April 2025 issue of Otolaryngology–Head and Neck Surgery. They talk about the risk of thyroid cancer for biological males taking estrogen compared to men not undergoing hormone therapy and women.   Click here to read the full article.

Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't."  "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI  reveal-dx.com Download the transcript here

Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't."  "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI  reveal-dx.com Listen to the podcast here

Sin is like cancer. Our whole nature is permeated by sin. In certain places it looks to be dormant but in other areas is causing destruction. Sin that is left unhindered will eventually impact the whole of a person and has the ability to infect other people.

Speaker: Adam GodshallSeries: "Respectable Sins" and SanctificationText: James 1; Numbers 13-14Theme: The Malignancy of Sin

In this interview Xander is joined by the guys in Malignancy before their show at The Brass Mug in Tampa! Excerpts from the Malignancy track "Existential Dread" (2024) used with permission from the artist. Check out Malignancy's music at https://www.youtube.com/@MalignancyNY Purchase music and merchandise from Malignancy at https://malignancy.bandcamp.com/music SOCIAL LINKS: Twitter: https://twitter.com/metaldebate/ Facebook: https://www.facebook.com/thegreatmetaldebate/ Instagram: https://www.instagram.com/metaldebate/ The Great Metal Debate Podcast: https://podcasts.apple.com/us/podcast/the-great-metal-debate-podcast/id1037874814 https://soundcloud.com/thegreatmetaldebate CONTACT Business email: TheGreatMetalDebate@gmail.com

Full article: Bosniak Classification of Cystic Renal Masses Version 2019: Proportion of Malignancy by Class and Subclass—Systematic Review and Meta-Analysis Aric Berning, MD, discusses the AJR article by McGrath et al. that provides a meta-analysis of malignancy proportions for Bosniak classification version 2019, stratified by class and subclass.

Commentary by Dr. Lorenzo Gervaso

Host: Darryl S. Chutka, M.D. Guest: Aaron M. Potretzke, M.D. Today, we're airing a popular episode from Season 2 of Mayo Clinic Talks!  Happy Holidays! Microscopic hematuria, and less commonly gross hematuria, are conditions commonly seen by the primary care provider. Malignancy is the most ominous cause of hematuria. Fortunately, other causes are much more likely. Since this is a relatively common health condition, when should we investigate hematuria and what should the evaluation consist of? How do we evaluate a patient's risk for urinary tract malignancy? Dr. Aaron Potretzke, a urologist at Mayo Clinic, joins us to discuss these questions. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

IBD Drive Time: Jordan Axelrad, MD, on Treating Patients With IBD and Malignancy by Gastroenterology Learning Network

Rheumatologists Dr. Jeffrey Curtis and Dr. Jon Giles discuss the risk of comorbidities that can occur as a consequence of uncontrolled inflammation in RA

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Epistemic states as a potential benign prior, published by Tamsin Leake on August 31, 2024 on The AI Alignment Forum. Malignancy in the prior seems like a strong crux of the goal-design part of alignment to me. Whether your prior is going to be used to model: processes in the multiverse containing a specific "beacon" bitstring, processes in the multiverse containing the AI, processes which would output all of my blog, so I can make it output more for me, processes which match an AI chatbot's hypotheses about what it's talking with, then you have to sample hypotheses from somewhere; and typically, we want to use either solomonoff induction or time-penalized versions of it such as levin search (penalized by log of runtime) or what QACI uses (penalized by runtime, but with quantum computation available in some cases), or the implicit prior of neural networks (large sequences of multiplying by a matrix, adding a vector, and ReLU, often with a penalty related to how many non-zero weights are used). And the solomonoff prior is famously malign. (Alternatively, you could have knightian uncertainty about parts of your prior that aren't nailed down enough, and then do maximin over your knightian uncertainty (like in infra-bayesianism), but then you're not guaranteed that your AI gets anywhere at all; its knightian uncertainty might remain so immense that the AI keeps picking the null action all the time because some of its knightian hypotheses still say that anything else is a bad idea. Note: I might be greatly misunderstanding knightian uncertainty!) (It does seem plausible that doing geometric expectation over hypotheses in the prior helps "smooth things over" in some way, but I don't think this particularly removes the weight of malign hypotheses in the prior? It just allocates their steering power in a different way, which might make things less bad, but it sounds difficult to quantify.) It does feel to me like we do want a prior for the AI to do expected value calculations over, either for prediction or for utility maximization (or quantilization or whatever). One helpful aspect of prior-distribution-design is that, in many cases, I don't think the prior needs to contain the true hypothesis. For example, if the problem that we're using a prior for is to model processes which match an AI chatbot's hypotheses about what it's talking with then we don't need the AI's prior to contain a process which behaves just like the human user it's interacting with; rather, we just need the AI's prior to contain a hypothesis which: is accurate enough to match observations. is accurate enough to capture the fact that the user (if we pick a good user) implements the kind of decision theory that lets us rely on them pointing back to the actual real physical user when they get empowered - i.e. in CEV(user-hypothesis), user-hypothesis builds and then runs CEV(physical-user), because that's what the user would do in such a situation. Let's call this second criterion "cooperating back to the real user". So we need a prior which: Has at least some mass on hypotheses which correspond to observations cooperate back to the real user and can eventually be found by the AI, given enough evidence (enough chatting with the user) Call this the "aligned hypothesis". Before it narrows down hypothesis space to mostly just aligned hypotheses, doesn't give enough weight to demonic hypothesis which output whichever predictions cause the AI to brainhack its physical user, or escape using rowhammer-type hardware vulnerabilities, or other failures like that. Formalizing the chatbot model First, I'll formalize this chatbot model. Let's say we have a magical inner-aligned "soft" math-oracle: Which, given a "scoring" mathematical function from a non-empty set a to real numbers (not necessarily one that is tractably ...

IBD Drive Time: Jordan Axelrad, MD, on IBD and Malignancy by Gastroenterology Learning Network

Canadian legends Rush are obviously huge around the RAM offices. And our own Aaron is a badass bassist as well. So of course we both got sucked right into the Paramount + mini series "Geddy Lee Asks 'Are Bass Players People Too' ". The bassist extraordinaire spends time with four major music movers and shakers that strum the four strings. The program sent our imaginations into overdrive. This week we fantasy book our own Season Two. Our picks range from some all time greats to underground underdogs to Lemmy (??!!). In our "News, Views and Tunes", we discuss Gojira at The Olympics. Musically, we crank some Ironflame, Tokyo Blade, Poison Idea, Malignancy, Helms Deep, Warlust and introduce Florida trad metallers Living Fast in our "Indie Spotlight". Horns Up!

Ep. 189 - Malignancy by Cali Death Podcast

To abruptly switch gears from our Very Special Episode earlier this week, we deliver reviews of the newest installments from two tech death giants. Ulcerate is back with their seventh full-length record which shows the band committing even more fully to the elements of post-rock, black metal, and textured drone which have helped define their sound- but have they strayed too far from the path? Pitted against them is the mutated monstrosity Malignancy's fourth full-length, which seeks to bring their sound a bit closer to the center of death metal while leaving their whiplashing, wild style of technicality intact- but can they maintain their vicious edge? YOU WOULD LIKE TO KNOW MORE. 0:00:00 - Intro 0:01:56 - Ulcerate - Cutting the Throat of God (Debemur Morti Productions) 0:54:35 - Interlude - The Brass - “Treading Water,” fr. the Rugged Cross EP (Independent, 2015) 0:58:44 - Malignancy - …Discontinued (Willowtip Records) 1:40:43 - Outro - Copremesis - “A Poem” fr. Muay Thai Ladyboys (Paragon Records, 2008) Terminus links: Terminus on Youtube Terminus on Patreon Terminus on Instagram Terminus on Facebook thetrueterminus@gmail.com

Welcome back to The Great Metal Debate podcast. Today we are talking about the fourth full-length studio album by the New York brutal tech death band Malignancy titled ...Discontinued, which was dropped on June 14th through Willowtip Records. This is the band's first album in 12 years so this certainly calls for celebration. For a band that has been around since 1992, you would think that they would have much more albums in their discography but, I guess some bands like to really take the time with their craft. Before diving into this new record track by track, I'm going point out a major similarity that I've always noticed about this band. Particularly with the vocalist Danny Nelson having a nearly identical sounding voice to Ross Dolan from Immolation. I had often wondered if Malignancy was a side project band, which would make a lot of sense seeing as how both bands are from Yonkers! The answer is no, Danny and Ross are two different people. However, Danny had done vocals for Mortal Decay's 2013 album The Blueprint For Blood Spatter. When I looked up the names of the band members, I had to do a double take when I saw the bass player. At first I thought it said Alex Webster from Cannibal Corpse, but nope, the new bass player is Alex Weber. Haha, not Webster. Coincidentally enough, guess where Cannibal Corpse originally started. You guessed it, New York. Except they formed in Buffalo. According to Metal-Archives, Alex Weber has played live for Defeated Sanity and Obscura. Guitarist Ron Kachnic has also been in Pyrexia, Demolition Hammer and Mortician! Mike Heller has been the drummer for multiple bands including System Divide which is Sven from Aborted's side project band. Despite not advertising as such, Malignancy IS a super group. Kicking things off we have the first track titled "Existential Dread". As you listen to this album, you can feel Danny's lips press against the microphone as he delivers his powerful vocals. You can tell he definitely uses his diaphragm to produce such a monstrous tone. Watch a few live videos of them and you can witness for yourself Danny's commanding stage presence too. "Purity of Purpose" was the first single released for this album about 2 months beforehand. I remembered as soon as I heard it, I immediately looked up the full-length release date and album title just to add it to my list. Judging from that track alone, I knew I had to review it. The second single "Biological Absurdity" was uploaded a month later and it of course blew me away. Both of these songs were aired on YouTube as official tracks but we haven't been treated to a music video yet. I have found myself jamming this album front to back since its release a little over a week ago and I gotta say, I'm impressed! I mean, Malignancy never disappoints. This album is absolutely killer and one of the finest examples of your standard death metal. Bad ass death metal albums without an overly unique pizazz quality about them are still more than capable of getting a good rating out of me. This is definitely one of the better straight forward death metal albums I've heard in 2024 so far. With that being said, I'm feeling a nice 8/10 rating. Malignancy has been kickin around in the underground scene since I was a 1-year-old. They've gone through a few line-up changes here and there but have held strong as a band for the past three decades. Their popularity may not be up on the same level as many other bands but they deserve a lot of credit, respect and most of all support. You can buy their merch ... at pretty much any online metal merch outlet. The most obvious choice would be bandcamp, but they also have merch at primitiverecordings.com, hellsheadbangers.com and indiemerch.com. Of course, if you get lucky enough to see them live; they definitely have a merch table and I hear that they are usually at their stand before and after a show. So don't be shy, go say hi and if nothing else, throw them a few bucks in their tip jar.

On this week's episode, Jon and Brandon discuss new releases from Charli XCX, Peggy Gou, KAYTRANADA, RM, NxWorries, The Early November, Malignancy, Vomit the Soul, Swelling Repulsion and more!   Intro Music by Anthony Reeder   Show Notes: Link To Weekly Rotating Playlist: https://open.spotify.com/show/6EE5pohSvSjm5ZFQf45iv1?si=32cab828e94d4a24

S10E260: Soundtrack for the Eclipse Lessons people wish they learned sooner, bizarre celebrity facts, sex stories, eclipse beliefs, did you know facts, a death row conversation, and heavy metal for your filthy earballs! (00:00:00) - Intro (00:00:57) - Malignancy, SONG: Purity of Purpose (00:04:46) - Deal with God, SONG: Imposter (00:07:06) - Conversation 1 (00:15:31) - Black Wound, SONG: Trench Blast (00:20:00) - Pantheon Omega, SONG: Invokation to War (00:24:42) - Conversation 2 (00:32:32) - Helms Deep, SONG: Serpent's Eye (00:36:17) - Abreaktion, SONG: Broken Promises (00:40:25) - Tusenårseken, SONG:Fattigdomens Köttkvarn (00:46:16) - Conversation 3 (00:52:56) - Grandma's Pantry: Abstrakt Algebra, SONG: Stigmata (00:58:28) - Conversation 4 (01:08:42) - GRAVKVADE, SONG: En Himlakropps Dödsbädd (01:17:06) - ARISTARCHOS, SONG: Oath: Dispersal of the Spectral Awning in Perpetual Flame (01:21:16) - Diabolic Oath, SONG: Rusted Madness Tethering Misbegotten Haruspices Labels: Willowtip Records, Chaos Records, Nameless Grave Records, Transylvanian Recordings, Vendetta Records, Sentient Ruin Laboratories

Episode One, Part Two of the “Real World LDRT” miniseries (sponsored by Xstrahl) circles back to the 1940s and the extraordinary flaws of the "linear no threshold" (LNT) model of radiation risk. We explore backroom deals, handshake science, corporate greed, regulatory capture, hormesis, OSHA violations, putting radium in the throats of 2.5 million children...you know, the regular, everyday stuff. Why? Because a common hesitation to deploying LDRT for arthritis is the risk of the treatment itself causing cancer. Spoiler alert: there has never been a case of secondary malignancy from therapeutic radiation below a magical threshold dose. And LDRT stays below that threshold. Don't believe me? That's why this miniseries exists! Relevant papers and sources at ⁠http://u.pc.cd/OhN⁠ Brought to you in part by Xstrahl, modern manufacturers of orthovoltage devices. Visit them at ⁠https://xstrahl.com/⁠ OOTB, produced by Photon Media, is made possible by Cold Light Legacy, a 501(c)(3) nonprofit that thrives on community support. jason@coldlight.org --- Support this podcast: https://podcasters.spotify.com/pod/show/radmed/support

Dr. Erica Golemis is a Professor, Deputy Chief Science Officer, Co-Leader of the Molecular Therapeutics Program, and Director of the High Throughput Facility at the Fox Chase Cancer Center in Philadelphia. In addition, Erica is an adjunct faculty member at the University of Pennsylvania, Drexel University School of Medicine, and the Temple University Lewis Katz School of Medicine. For most of her scientific career, Erica has been conducting cancer research. Her recent work investigates why some cancers are particularly malignant. Erica's research examines what genes cause cancer to change and progress, whether there are genes that can be targeted directly with different treatments to reverse this process, and if there is a therapeutic time window in which they could potentially reverse this process. When Erica finds free time, one thing she loves to do is read. She reads broadly and has been an avid reader since her early childhood. Erica also has fun attending theatre performances. There are multiple excellent theaters in her home city of Philadelphia, and she especially enjoys shows by British playwright Tom Stoppard. She completed her undergraduate studies in biology and English at Bryn Mawr College and was awarded her PhD in biology from the Massachusetts Institute of Technology. Afterwards, Erica conducted postdoctoral research at the Massachusetts General Hospital Department of Molecular Biology and Harvard Medical School department of Genetics before joining the Fox Chase Cancer Center. In this interview, Erica speaks about her experiences in both life and science.

In this week's episode we'll discuss the findings from a prospective trial of TCRαβ/CD19-cell depleted HLA-haploidentical transplantation to treat pediatric acute leukemia, learn more about the incidence, clinical characteristics, and survival of malignancy-associated hemophagocytic lymphohistiocytosis in Sweden, and discuss the bone marrow as the primary site of thrombopoiesis. 

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency's policy for using background music in direct-to-consumer advertising (7:27), and the FDA's new incoming principal deputy commissioner (13:44). More On These Topics From The Pink Sheet CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology: https://pink.citeline.com/PS149420/CAR-T-Malignancy-Reports-Could-Temper-Excitement-For-Use-Beyond-Oncology Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy: https://pink.citeline.com/PS149411/Background-Music-During-Risk-Segment-Of-Rx-Drug-Ads-FDA-Explains-Its-Policy US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner: https://pink.citeline.com/PS149428/US-FDA-Chief-Scientist-Bumpus-Will-Become-Principal-Deputy-Commissioner

Full article: https://www.ajronline.org/doi/10.2214/AJR.23.29826  Hong Linda Li, MD discusses a new article that examines the need for a comprehensive approach that integrates clinical, radiological, and histopathological data for accurate diagnosis and management of adrenal masses.

Have you ever wondered about how to treat VTE in malignancy? This episode goes over all the ins and outs of this complex and nuanced topic! Written by Dr. Kevin Yijun Fan, Internal Medicine and reviewed by Dr. Helena Dhamko, (Hematology) and Dr. Ed Etchells (General Internal Medicine).  Infographic by Valarie Kim (Internal Medicine Resident). Support the show

Radiation oncology in GI malignancy (endpoints and stratification) in the JCO

Sam talks with writer and historian Paul Street (also on the RefuseFascism.org Editorial Board) about recent events including the fascist attempts to shut down the government, the ouster of Kevin McCarthy from the Speaker of the House, and the increasingly violent threats and promises of vengeance from current frontline candidate for president and as-yet unconvicted coup plotter Donald Trump. Follow Paul on his Substack and read his latest article, Nether the Fascist Trump Nor Imperialist Biden Mentioned in this episode: America needs to talk about the right's ‘Red Caesar' plan for U.S. dictatorship by Will Bunch Trump's Bloody Campaign Promises by David Remnick Related episodes: Fascism In America: Past and Present Trump Indicted and Media Complicity in the Rise of Fascism The Fantasy of the Reasonable Republican  How to help the show? Rate and review wherever you get your podcasts; share with your friends! Get involved at RefuseFascism.org. We're still on Twitter (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@RefuseFascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and other social platforms including Threads, Mastodon and Bluesky. Send  your comments to samanthagoldman@refusefascism.org or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@SamBGoldman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Record ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠a voice message for the show here. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Connect with the movement at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠RefuseFascism.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and support: · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠paypal.me/refusefascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠donate.refusefascism.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/refusefascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music for this episode: Penny the Snitch by Ikebe Shakedown --- Send in a voice message: https://podcasters.spotify.com/pod/show/refuse-fascism/message

Dr. Refky Nicola discusses the potential role of contrast-enhanced US in the differentiation of malignant and benign lesions with Dr. Edward Grant.   Contrast-enhanced US to Improve Diagnostic Performance of O-RADS US Risk Stratification System for Malignancy. Yuan et al. Radiology 2023; 308(2):e223003.   Adding Contrast-enhanced US to O-RADS: A Route to Improved Specificity? Grant. Radiology 2023; 308(2):e231483.

Join us as we review recent articles and news featured in The DIGEST #43 and #44, including bempedoic acid to lower cardiovascular risk, Alpha-Gal Syndrome, tick bites and meat allergy, orforglipron an oral GLP1 agonist for weight loss, zuranolone for postpartum depression, DOACs for VTE of malignancy, monoclonal antibodies (mAbs) for Dementia, cytisinicline for smoking cessation, and two kiwis a day for constipation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto), and Matt Watto (@doctorwatto). Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | Free CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewers: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Sponsor: Netsuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance for free, at NetSuite.com/CURBSIDERS Sponsor: Locumstory  Get a comprehensive view of locums and decide if it's right for you at locumstory.com. Sponsor: Grammarly  Go to grammarly.com/GO to download for FREE today. Sponsor: Pathway Download the Pathway app today by visiting pathway.md Show Segments Intro, disclaimer Bempedoic Acid for CV risk reduction DOACs to prevent recurrent VTE of malignancy Cytisinicline for smoking cessation Alpha-Gal Syndrome, tick bites, and meat allergy Zuranolone for postpartum depression Orforglipron, an oral GLP1 agonist, for weight management mAbs for Alzheimer's dementia Kiwis to prevent constipation Outro